These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19301031)

  • 61. Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.
    Cuzick J; Yang ZH; Fisher G; Tikishvili E; Stone S; Lanchbury JS; Camacho N; Merson S; Brewer D; Cooper CS; Clark J; Berney DM; Møller H; Scardino P; Sangale Z;
    Br J Cancer; 2013 Jun; 108(12):2582-9. PubMed ID: 23695019
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
    Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
    Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Utility of ERG versus AMACR expression in diagnosis of minimal adenocarcinoma of the prostate in needle biopsy tissue.
    Andrews C; Humphrey PA
    Am J Surg Pathol; 2014 Jul; 38(7):1007-12. PubMed ID: 24705308
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Enzymatic prostatic acid phosphatase in the clinical staging of patients diagnosed with prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Allen Z; DeFilippo JL; Adamovich E
    W V Med J; 2005; 101(3):116-9. PubMed ID: 16161529
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Preoperative prediction of small volume cancer (less than 0.5 ml) in radical prostatectomy specimens.
    Cheng L; Poulos CK; Pan CX; Jones TD; Daggy JK; Eble JN; Koch MO
    J Urol; 2005 Sep; 174(3):898-902. PubMed ID: 16093983
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
    Jiang Z; Woda BA; Wu CL; Yang XJ
    Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Is there a role for prostate tumour overexpressed-1 in the diagnosis of HGPIN and of prostatic adenocarcinoma? A comparison with alpha-methylacyl CoA racemase.
    Scarpelli M; Mazzucchelli R; Barbisan F; Santinelli A; Lopez-Beltran A; Cheng L; Montironi R
    Int J Immunopathol Pharmacol; 2012; 25(1):67-74. PubMed ID: 22507319
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
    Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
    Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The significance of the P504S expression pattern of high-grade prostatic intraepithelial neoplasia (HGPIN) with and without adenocarcinoma of the prostate in biopsy and radical prostatectomy specimens.
    Helpap B
    Virchows Arch; 2006 Apr; 448(4):480-4. PubMed ID: 16506014
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Alpha-methylacyl CoA racemase in pulmonary adenocarcinoma, squamous cell carcinoma, and neuroendocrine tumors: expression and survival analysis.
    Shilo K; Dracheva T; Mani H; Fukuoka J; Sesterhenn IA; Chu WS; Shih JH; Jen J; Travis WD; Franks TJ
    Arch Pathol Lab Med; 2007 Oct; 131(10):1555-60. PubMed ID: 17922592
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Alpha-methylacyl-CoA racemase (AMACR) in fine-needle aspiration specimens of prostate lesions.
    Kaić G; Tomasović-Loncarić C
    Diagn Cytopathol; 2009 Nov; 37(11):803-8. PubMed ID: 19459159
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Utility of tissue microarrays for profiling prognostic biomarkers in clinically localized prostate cancer: the expression of BCL-2, E-cadherin, Ki-67 and p53 as predictors of biochemical failure after radical prostatectomy with nested control for clinical and pathological risk factors.
    Nariculam J; Freeman A; Bott S; Munson P; Cable N; Brookman-Amissah N; Williamson M; Kirby RS; Masters J; Feneley M
    Asian J Androl; 2009 Jan; 11(1):109-18. PubMed ID: 19050681
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prostate cancer detection on urinalysis for alpha methylacyl coenzyme a racemase protein.
    Rogers CG; Yan G; Zha S; Gonzalgo ML; Isaacs WB; Luo J; De Marzo AM; Nelson WG; Pavlovich CP
    J Urol; 2004 Oct; 172(4 Pt 1):1501-3. PubMed ID: 15371879
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Utility of RhoC and ZAG protein expression as biomarkers for prediction of PSA failure following radical prostatectomy for high grade prostate cancer.
    Mills J; Oliver A; Sherwin JC; Frydenberg M; Peters JS; Costello A; Harewood L; Love C; Redgrave N; van Golen KL; Bailey M; Pedersen J
    Pathology; 2012 Oct; 44(6):513-8. PubMed ID: 22935975
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Human telomerase and alpha-methylacyl-coenzyme A racemase in prostatic carcinoma. A comparative immunohistochemical study.
    Puebla-Mora AG; Heras A; Cano-Valdez AM; Domínguez-Malagón H
    Ann Diagn Pathol; 2006 Aug; 10(4):205-8. PubMed ID: 16844561
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Can stage A1 tumor extent be predicted by transurethral resection tumor volume, per cent or grade? A study of 64 stage A1 radical prostatectomies with comparison to prostates removed for stages A2 and B disease.
    Larsen MP; Carter HB; Epstein JI
    J Urol; 1991 Oct; 146(4):1059-63. PubMed ID: 1895422
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy.
    Farinola MA; Epstein JI
    Hum Pathol; 2004 Oct; 35(10):1272-8. PubMed ID: 15492996
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
    Kunju LP; Chinnaiyan AM; Shah RB
    Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.